Sanofi announces voluntary recall of Zantac products
The pharmaceutical company Sanofi is voluntarily recalling its OTC Zantac products in the US and Canada due possible contamination with NDMA.
List view / Grid view
The pharmaceutical company Sanofi is voluntarily recalling its OTC Zantac products in the US and Canada due possible contamination with NDMA.
Torrent Pharmaceuticals has received a warning letter from the FDA for violating cGMP regulations at its manufacturing facility in India.
Compounded drug products are being voluntarily recalled due a lack of sterility assurance.
Custom manufacturing of specialty chemicals and APIs.
The UK MHRA has issued an alert for the recall of unexpired Zantac products made by GSK due to the possible contamination of ranitidine in the medicines.
The CQC decision marks the first time the agency has accepted a clinic to prescribe patients with medical cannabis in the UK.
4 October 2019 | By Mettler-Toledo GmbH
This webinar provides an overview of the important UV/Vis spectroscopy-relevant changes in both USP and Ph. Eur. taking a closer look at their impact and the solutions available to ensure compliance.
The FDA recommends drug manufacturers to use LC-HRMS to test for NDMA in ranitidine products, as high temperatures generate the impurity.
The FDA and DEA have, for the first time, sent joint warning letters to four networks which were illegally selling opioid products.
2 October 2019 | By SUEZ – Ozonia® Ozone Systems
This webinar guides you through efficiency gains with TOC for cleaning validation. We call it a ‘beginner’s guide’, but the session will benefit long-time TOC users as well as those new to using TOC for cleaning validation.
CPhI Worldwide now comprises six individual pharma events and more than 20 dedicated zones.
In an effort to prevent harm through contamination, the U.S. Pharmacopeial Convention has been working on a series of proposed changes to USP Chapter 797, Pharmaceutical Compounding– Sterile Preparations.
A survey of pharmacists has discovered that UK pharmacies experienced shortages across all 36 medicine categories in the last six months.
The European Medicines Agency has issued advice to pharmaceutical companies on how to avoid the presence of nitrosamines in medicines.
This article explores the potential of readily available technology to address current traceability challenges as well as more wide-ranging issues in the pharmaceutical industry.